darunavir

Darunavir expanded access

Graham Stocks — Thu, 10 Jun 2010 23:28:25 -0700

The Pharmaceutical Benefits Scheme[Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs. (PBS) has extended access to the new protease inhibitorA type of anti-HIV drug that works by preventing the production of an enzyme, protease, that HIV needs to replicate., darunavir, now making it an option for more people.

AIDS 2008: Is the HIV drug pipeline drying up?

David Menadue — Tue, 23 Sep 2008 19:21:56 -0700

The International AIDS Conference heard promising reports about the newer HIV treatments designed to help treat people with advanced and drug-resistantHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant. HIV, all of which are now available in Australia.

Darunavir and the risk of hepatitis

admin — Mon, 21 Jul 2008 18:10:05 -0700

A warning has been issued by Tibotec, the manufacturers of Prezista (darunavir) regarding the risk of developing drug- induced hepatitis while taking the treatment.

Good news, bad news: report from CROI

admin — Tue, 25 Mar 2008 18:58:42 -0700

John Daye, NAPWA's Health, Treatments & Research Portfolio Co-Convenor reports from the 15th Conference on Retroviruses and Opportunistic Infections (CROI) held in Boston, USA from 3-6 February 2008

ASHM 2006: Strategies for coping with multiple drug resistance

Paul Kidd — Wed, 20 Dec 2006 06:07:10 -0800

Finding effective treatment options for people who have taken many treatments and have multiple resistanceHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant. mutations continues to be a significant challenge for HIV clinicians, and their patients.

Time to deliver

John Daye — Wed, 04 Oct 2006 07:10:48 -0700

The 16th International AIDS Conference highlighted numerous important and promising developments in HIV treatments. JOHN DAYE reports.

Looking forward, looking back

Wed, 12 Jul 2006 07:08:19 -0700

In September 2006, the International Association of Physicians in AIDS Care will mark a decade of highly active antiretroviralA medication or other substance which is active against retroviruses such as HIV. therapy. Has it really been 10 years since the so-called Protease Moment? KIRSTY MACHON reports on where we have come from – and where to from here.

Rocky Mountain CROI

Paul Kidd — Wed, 26 Apr 2006 07:08:00 -0700

The 13th annual Conference on Retroviruses and Opportunistic Infections (CROI) took place in Denver, Colorado, from February 5 to 8. The major breaking news from this conference was the premature cancellation of the SMART study, but as usual, this important conference produced a great deal more than a single story.

News and treatments briefs

Paul Kidd — Wed, 26 Apr 2006 07:05:13 -0700

HIV-related news in brief from the April 2006 edition of Positive Living.

Much more than a junket

Paul Kidd — Wed, 12 Oct 2005 07:08:03 -0700

A report from the 3rd IAS Conference on HIV Pathogenesis and Treatment, held in Rio de Janiero in July.